Renalytix Plc - רווח למניה ב-12 החודשים האחרונים RNLX

סמלים רשמיים של חברת Renalytix, plc (RNLX)

Renalytix Plc (RNLX) develops KidneyIntelX AI systems that integrate medical records with biomarkers for precise kidney diagnostics. The annual EPS growth rate over the last 12 months on the GURU.Markets base chart confirms profit dynamics, where 20.80 determines the latest valuation metric. Strong pricing power is driven by the critical nature of dialysis prevention, although a heavy reliance on a single product and slow insurance company approvals create risks.

RNLX: רווח נקי למניה (EPS TTM) Renalytix, plc 11.02.2024 - 20.02.2024

RNLX (Renalytix Plc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר שוק ויעדי מחיר של אנליסטים:
הערכת שווי פונדמנטלית של החברה:RNLX, Renalytix PLC
מוצר עיקרי של Renalytix, plc

Renalytix Plc (RNLX) monetizes its AI platform through strategic partnerships with hospitals to optimize kidney disease therapy. The TTM net income per share annual growth rate illustrates the efficiency of this model in generating capital. This metric measures the percentage change in earnings over the last twelve months, smoothing out volatility between quarterly reports. The upward trend confirms the scalability of the business; however, extreme peaks may signal an impending growth slowdown.